Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Institut de Recherches Internationales Servier: Clinical Trials & FDA Approval Profile

Institut de Recherches Internationales Servier (Global / Institutional) sponsors 22 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (3 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)27.3%
Median Closed Enrollment vs National (145 pts)56 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Institut de Recherches Internationales Servier
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)22
Active Pipeline (Recruiting Now)7 (3)
Completed vs Stopped Early9 / 6 (27.3%)
Median Closed Actual Enrollment56 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Institut de Recherches Internationales Servier
Hospital Research SiteLocationShared Protocols
MD Anderson Cancer CenterHouston, TX6
Memorial Sloan Kettering Cancer CenterNew York, NY5
Duke University Medical CenterDurham, NC5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Institut de Recherches Internationales Servier
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06465953Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic SyndromesPhase IIIRECRUITING
NCT04164901Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)Phase IIIACTIVE NOT RECRUITING
NCT03869892Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.Phase IIIACTIVE NOT RECRUITING
NCT05820880Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionPhase IIICOMPLETED
NCT04817761SPARK-ALL: Calaspargase Pegol in Adults With ALLPhase II/IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Institut de Recherches Internationales Servier Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI